Neuro

Radius Provides Agenda for Today’s R&D Webcast

Retrieved on: 
Tuesday, April 5, 2022
Company, Private Securities Litigation Reform Act, Risk, Partnership, Investor, Osteoporosis, Prader–Willi syndrome, Neuro, SEC, Woman, Food, U.S. Securities and Exchange Commission, Man, Media relations, RAD1901, Spasm, International, Angelman syndrome, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Fracture, Neuropsychiatric Disease and Treatment, Annual report, Patient, Security (finance), Broadcasting, Pharmaceutical industry, Public relations, Radius

A live audio webcast of the call can be accessed from the Investors section of the Companys website, www.radiuspharm.com .

Key Points: 
  • A live audio webcast of the call can be accessed from the Investors section of the Companys website, www.radiuspharm.com .
  • To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 9678881.
  • The live audio webcast of the call can be accessed from the Investors section of the Companys website, https://ir.radiuspharm.com/events-and-presentations .
  • Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology.

Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting

Retrieved on: 
Friday, April 1, 2022
Abdomen, Private Securities Litigation Reform Act, Therapy, Face, GSK, Population, Poster, Muscular dystrophy, MFI, Gene expression, Facioscapulohumeral muscular dystrophy, Neuro, Hemoglobinopathy, HIV disease progression rates, Fulcrum, Thalassemia, Fetal hemoglobin, Quality, Ascending limb of loop of Henle, DUX4, Efficacy, Patient, Â, U.S. Securities and Exchange Commission, Food, Quality of life, RWS, Security (finance), MD, Chronic pain, Review, Food and Drug Administration, REACH, Muscle, Nasdaq, GLOBE, American Academy, Area studies, Sickle cell disease, PDT, AAN, MRI, FDA, Scapula, MAPK, PGIC, Pharmaceutical industry, Risk management, Paint, Safety, Losmapimod, FSHD

CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple oral and poster presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) at the American Academy of Neurology’s Annual Meeting, taking place April 2-7 in Seattle, WA. These presentations highlight clinical data supporting the potential of losmapimod as well as the design of the Phase 3 REACH trial of losmapimod in FSHD.

Key Points: 
  • These presentations highlight clinical data supporting the potential of losmapimod as well as the design of the Phase 3 REACH trial of losmapimod in FSHD.
  • FSHD is a progressive, relentless, and debilitating disease for which there are no approved therapies, said Christopher Morabito, MD, Fulcrums chief medical officer.
  • The presentations will also be available for viewing to registered conference attendees during the virtual AAN 2022 Annual Meeting taking place April 24-26.
  • However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

Vielight pushes photobiomodulation research to a new level.

Retrieved on: 
Tuesday, March 29, 2022
PBM, Leadership, Neuro, PTSD, Gulf War syndrome, Research, Doctor of Philosophy, CEO, Health, LMHC, TBI, Meditation, COVID-19, Brain, GLOBE, Science, Founder, Depression, Medical imaging, BCN

Toronto, Canada, March 29, 2022 (GLOBE NEWSWIRE) -- Vielight Inc., a global leader in transcranial photobiomodulation (tPBM) research, development and manufacturing, is pleased to announce a new system: the Neuro Pro .

Key Points: 
  • Toronto, Canada, March 29, 2022 (GLOBE NEWSWIRE) -- Vielight Inc., a global leader in transcranial photobiomodulation (tPBM) research, development and manufacturing, is pleased to announce a new system: the Neuro Pro .
  • To date, applications and research into tPBM have been largely confined to pulse frequencies of 0Hz, 10Hz, and 40Hz.
  • Vielight devices are used in research studies and clinical trials worldwide covering:
    Alzheimers disease, Parkinsons disease, TBI/concussion/CTE, PTSD, Gulf War Syndrome, depression, COVID-19, sports performance, and meditation.
  • Vielight Inc. is also active in basic science research of biological mechanisms that translate into better personalization.

Vielight pushes photobiomodulation research to a new level.

Retrieved on: 
Tuesday, March 29, 2022
PBM, Leadership, Neuro, PTSD, Gulf War syndrome, Research, Doctor of Philosophy, CEO, Health, LMHC, TBI, Meditation, COVID-19, Brain, GLOBE, Science, Founder, Depression, Medical imaging, BCN

Toronto, Canada, March 29, 2022 (GLOBE NEWSWIRE) -- Vielight Inc., a global leader in transcranial photobiomodulation (tPBM) research, development and manufacturing, is pleased to announce a new system: the Neuro Pro .

Key Points: 
  • Toronto, Canada, March 29, 2022 (GLOBE NEWSWIRE) -- Vielight Inc., a global leader in transcranial photobiomodulation (tPBM) research, development and manufacturing, is pleased to announce a new system: the Neuro Pro .
  • To date, applications and research into tPBM have been largely confined to pulse frequencies of 0Hz, 10Hz, and 40Hz.
  • Vielight devices are used in research studies and clinical trials worldwide covering:
    Alzheimers disease, Parkinsons disease, TBI/concussion/CTE, PTSD, Gulf War Syndrome, depression, COVID-19, sports performance, and meditation.
  • Vielight Inc. is also active in basic science research of biological mechanisms that translate into better personalization.

VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference

Retrieved on: 
Thursday, March 24, 2022
Maxim, Company, Therapy, Marketing, Neuro, Central nervous system, CNS, Risk, SEC, Social anxiety disorder, Conference, PH94B, Industry, U.S. Securities and Exchange Commission, Nasdaq, COVID-19, Brain, GLOBE, Neuron, Anxiety, Central nervous system disease, SAN, Depression, FDA, Annual report, Pharmaceutical industry

In addition to his fireside chat, Mr. Singh will provide a recorded corporate presentation, available on demand to all registered conference attendees, during which he will highlight VistaGens pipeline, recent achievements, and anticipated milestones.

Key Points: 
  • In addition to his fireside chat, Mr. Singh will provide a recorded corporate presentation, available on demand to all registered conference attendees, during which he will highlight VistaGens pipeline, recent achievements, and anticipated milestones.
  • A link to the recorded presentation may be found on the Events page within the Investors section of the VistaGen website , beginning Monday, March 28, 2022, at 6:00 a.m. Pacific Time.
  • VistaGen (Nasdaq: VTGN) is a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders.
  • Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by VistaGen and its management, are inherently uncertain.

Fujirebio Confirms Its Engagement in Blood-based Alzheimer’s Disease Biomarker Testing with the Launch of the Fully Automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma Assays for Research Use Only

Retrieved on: 
Wednesday, March 30, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Fujirebio, Biomarker, Organization, Neurodegeneration, Plasma, Diagnosis, Neuro, IVD, Research, Innogenetics, Amyloid, CEO, Laboratory, Tau, Cerebrospinal fluid, CSF, Medical device

Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G -Amyloid 1-42 Plasma and Lumipulse G -Amyloid 1-40 Plasma assays for the fully automated LUMIPULSE G immunoassay systems.

Key Points: 
  • Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G -Amyloid 1-42 Plasma and Lumipulse G -Amyloid 1-40 Plasma assays for the fully automated LUMIPULSE G immunoassay systems.
  • These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of -amyloid1-42 and -amyloid1-40 in human plasma within just 35 minutes.
  • The two new automated blood-based biomarker assays are available for Research Use Only.
  • These four CSF parameters can provide essential information on the presence of amyloid and tau pathology in neurodegenerative disease.

Insights on the Neuro-Gaming Technology Global Market to 2027 - Education Segment to Witness Significant Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 29, 2022
Hardware, Electronic Games, Consumer Electronics, Technology, Entertainment, Adoption, Video, ESA, Life, Dyslexia, Television, United Kingdom, Growth, CDC, Developmental disorder, Neuro, UKIE, Mental disorder, Ageing, The Association for UK Interactive Entertainment, Autism, Government budget balance, NCHA, Learning, Association, Industry, Technology, EEG, Disorder, Student, Child, ADHD, Awareness, Efficiency, Depression, IPad, Pharmaceutical industry, Toy, Video game

Vendors in the market are putting efforts to make games for the healthcare industry.

Key Points: 
  • Vendors in the market are putting efforts to make games for the healthcare industry.
  • The company has also mentioned that the game measures 65 different pieces of data every second through the gameplay itself.
  • The continuous growth of the gaming industry is further driving the growth of the neuro-gaming technology market in the region.
  • Neuro-gaming technology is capable of solving these issues and limit any further transition to more significant problems later in life.

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple Sclerosis

Retrieved on: 
Monday, March 28, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Company, Therapy, LinkedIn, Multiple sclerosis, Trial of the century, Pharmacokinetics, Remyelination, Neuro, CNS, Program, Pathology, CEO, Food, Senior, Learning, Safety, MS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Even and odd functions, Attention, FDA, PET, RRMS, Patient, M1, Pharmaceutical industry, Medical imaging, Pipeline, PIPE-307 FOR MULTIPLE SCLEROSIS, PIPELINE THERAPEUTICS

FDA clearance to initiate our Phase 1b/2a clinical study of PIPE-307 is a major regulatory milestone for Pipeline, as it allows us to proceed with the evaluation of PIPE-307 in RRMS patients, said Carmine Stengone, President and CEO of Pipeline.

Key Points: 
  • FDA clearance to initiate our Phase 1b/2a clinical study of PIPE-307 is a major regulatory milestone for Pipeline, as it allows us to proceed with the evaluation of PIPE-307 in RRMS patients, said Carmine Stengone, President and CEO of Pipeline.
  • Our objective with PIPE-307 is to develop the first effective treatment that can restore myelin and improve outcomes for patients.
  • The Phase 1b/2a clinical trial of PIPE-307 will be conducted as a randomized, double-blind, placebo-controlled dose-ranging study in multiple sites across the US.
  • In March 2022, the Company received clearance from the U.S. Food and Drug Administration to proceed with a Phase 1b/2a study of PIPE-307 in RRMS patients.

Luna Recovery Services Now Providing Neurofeedback to Treat Addiction and Mental Health Disorders

Retrieved on: 
Wednesday, March 30, 2022
PBM, Rehabilitation, Somnolence, Neuro, Multimedia, Addiction medicine, Research, HIPPA, Specialization, Passages Malibu, EEG, Outpatient commitment, Neurology, Brain, LCSW, Science, Quantitative electroencephalography, Anxiety, HRV, Irritability, Patient, BCB, Depression, Mini, Partnership, Medical imaging, Low-level laser therapy, BCN, Neurofeedback

HOUSTON, March 30, 2022 /PRNewswire/ -- Luna Recovery Services, a drug, and alcohol rehabilitation treatment center, will be extending its treatment options to include Neurofeedback and more via its new Luna Neuro practice.

Key Points: 
  • HOUSTON, March 30, 2022 /PRNewswire/ -- Luna Recovery Services, a drug, and alcohol rehabilitation treatment center, will be extending its treatment options to include Neurofeedback and more via its new Luna Neuro practice.
  • The rehabilitation treatment will cater to the growing need for specialization in brain health to treat addiction and other conditions.
  • Electroencephalogram Biofeedback (EEG), also known as Neurofeedback, is a non-invasive treatment used to target the brain's neural networks.
  • Luna Recovery is based in Houston, Texas, and is continuously adding more value to their services to better help their clients and loved ones regain normalcy and peace of mind.

Curative Biotechnology Announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration

Retrieved on: 
Monday, March 21, 2022
Rabies, Degenerative disease, Diabetic retinopathy, Center for Epidemiologic Studies Depression Scale, Vaccine, Research, Office of Inspector General, U.S. Department of Health and Human Services, Cooperative research and development agreement, Securities Exchange Act of 1934, Securities Act of 1933, GLOBE, OTC, Disease, Retina, National, Neuro, Biotechnology, Human services, Metformin, NIH, Eye, Development, Geographic atrophy, NEI, OTC Markets Group, AMD, DECA, Review, Historical annual reformulations of the influenza vaccine, Severe cognitive impairment, Center, Homeland Security Act of 2002, Company, National Eye Institute, CRADA, Stockholm Environment Institute US Center, Judgement, Neoplasm, Effective date, Cooperative, Infection, CD56, Division, Pharmaceutical industry, Epidemiology

Boca Raton, FL, March 21, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI), a part of the National Institutes of Health (NIH).

Key Points: 
  • Under a Cooperative Research and Development Agreement (CRADA), the National Eye Institute and Curative Biotechnology, Inc. will collaborate to evaluate Curatives proprietary ocular metformin formulation in clinical studies for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
  • TITLE OF CRADA: Clinical Evaluation of Curative Biotechnology, Inc.s Proprietary Ocular Metformin Formulation
    Collaborator Principal Investigator Steering committee lead representative Dr. Catherine Sohn
    TERM OF CRADA: Three (3) years from the Effective Date.
  • is the Director of the Division of Epidemiology and Clinical Applications (DECA) at the National Eye Institute, the National Institutes of Health in Bethesda, Maryland.
  • Her research interest includes phase I/II clinical trials and epidemiologic studies in retinovascular diseases such as age-related macular degeneration, diabetic retinopathy, and other ocular diseases.